Skip to content

Jason P Rhodes, Director at Dyne Therapeutics, sold DYN on Jun 26, 2026

Data as of Oct 16

▼ SELL$1.4M64,411 shares at $21.28Jason P Rhodes DirectorDYN Dyne Therapeutics, Inc.
Watch DYN
Traded
Jun 26, 2026
Disclosed
Jun 30, 2026
Filed
4 days after the trade

Form 4s are due within two business days.

Official filing (SEC Form 4) ↗

The price around the disclosure

Jason P Rhodes, Director at Dyne Therapeutics, sold DYN on Jun 26, 2026TRADEDDISCLOSED
DYNSimilar stocks (XLV — its sector index fund), rebased to DYN's price on the disclosure day
DYN since disclosure
−35.8%
after the sale
Similar stocks (XLV) since disclosure
+11.4%
XLV — its sector index fund

Change in closing price from Jun 30, 2026 (the first trading day on or after disclosure) to Oct 16, 2026. Dividends excluded. Not a return anyone earned.

Our take

None of our tested rules fired on this trade.

Other trades in the same filing

  1. ▼ SELLJason P Rhodes DirectorDYN Dyne Therapeutics, Inc.$2.2Mdisclosed Jun 30 · filed 1 day after the trade
  2. ▼ SELLJason P Rhodes DirectorDYN Dyne Therapeutics, Inc.$1.1Mdisclosed Jun 30 · filed 1 day after the trade
  3. ▼ SELLJason P Rhodes DirectorDYN Dyne Therapeutics, Inc.$860Kdisclosed Jun 30 · filed 1 day after the trade
  4. ▼ SELLJason P Rhodes DirectorDYN Dyne Therapeutics, Inc.$3.5Mdisclosed Jun 30 · filed 4 days after the trade
  5. ▼ SELLJason P Rhodes DirectorDYN Dyne Therapeutics, Inc.$1.7Mdisclosed Jun 30 · filed 4 days after the trade

See every trade on DYN →